ARTICLE | Company News
Clinigen launches European managed access program for Beleodaq from Onxeo
May 12, 2017 8:37 PM UTC
Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq will be available on a named patient basis in the U.K., Germany, France, Spain, Italy, Denmark, Sweden, Norway, Finland, Belgium, the Netherlands, Luxembourg and Austria...
BCIQ Target Profiles